 
## Ticarcillin

### Preparation 

Available as powder for injection in 3.1-g vials. Reconstitute vial by adding 13 mL of sterile water for injection. Dilute further with a compatible solution to a concentration between 10 and 100 mg/mL. Dilutions are stable for 24 hours at room temperature, 3 days refrigerated (D5W), and 7 days refrigerated (NS and LR). Frozen dilutions stable for 7 days for D5W and 30 days for NS and LR. Contains 4.5 mEq (103.6 mg) of sodium per gram of ticarcillin/clavulanate.


### General dosing

Children and Adolescents: IV: 200 to 300 mg ticarcillin/kg/day in divided doses every 4 to 6 hours; maximum single dose: 3 g ticarcillin/dose.

### Dosing: Liver Impairment: Pediatric
No dosage adjustments necessary.

### Dosing: Kidney Impairment: Pediatric
Adjust dose in renal dysfunction. (2,13)  If CrCl is  > 30 mL/min, give a normal dose; if CrCl is 
10 – 29 mL/min, give 50 – 75 mg/kg q 8 hr; if  < 10 mL/min, give 50 – 75 mg/kg q 12 hr; and 
if  < 10 mL/min and hepatic insuf ciency, give 50 – 75 mg/kg q 24 hr. (13)  Alternatively, the 
manufacturer recommends if CrCl 30 – 60 mL/min, give a two-third normal dose q 4 hr; 
if CrCl 10 – 30 mL/min, give a two-third dose q 8 hr; if CrCl  < 10 mL/min, give a two-third 
dose q 12 hr; and if CrCl  < 10 mL/min with hepatic insuf ciency, give a two-third dose 
q 24 hr. (2) 

### Contraindications   
Seizures may occur when administered at very high doses and in the presence of renal impairment. Sodium content should be considered when treating patients requiring salt restrictions (4.5 mEq (103.6 mg) of sodium per gram of ticarcillin/clavulanate).


### Warnings/Precautions
Eosinophilia. Hyperbilirubinemia. Elevations in ALT, AST, BUN, and serum creatinine. Hypernatremia may be exacerbated in ELBW patients.


### Administration
- Maximum concentration: 43 mg/mL in NS, 48 mg/mL in D5W, and 86 mg/mL in SW
- Intermittent infusion: Over 30 minutes.
- IV push: not used
- Suitable diluents D5W, LR, and NS.

### Dosing for neonate
Dose 75 to 100 mg/kg/dose IV infusion by syringe pump over 30 minutes.

PMA is the primary determinant of dosing interval, with Postnatal Age as the secondary qualifier.
-	PMA (≤ 29 weeks) and PostNatal (0 to 28 days) - Interval (12 hours)
-	PMA (≤ 29 weeks) and PostNatal (> 28 days) - Interval (8 hours)
-	PMA (30 - 36 weeks) and PostNatal (0 to 14 days) - Interval (12 hours)
-	PMA (30 – 36 weeks) and PostNatal (> 14 days) - Interval (8 hours)
-	PMA (37 – 44 weeks) and PostNatal (0 to 7 days) - Interval (12 hours)
-	PMA (37 – 44 weeks) and PostNatal (> 7 days) - Interval (8 hours)
-	PMA (> 45 weeks) - Interval (6 hours) 


### Terminal Injection Site Compatibility
Dex/AA solutions. Aztreonam, cefepime, famotidine, fluconazole, heparin, insulin, milrinone, morphine, propofol, remifentanil, and theophylline.

### Terminal Injection Site Incompatibility
ADex/AA solutions. Aztreonam, cefepime, famotidine, fluconazole, heparin, insulin, milrinone, morphine, propofol, remifentanil, and theophylline.